Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.68 |
| ▸ | RAB9A | P51151 | 10/20 | 0.68 |
| ▸ | HTT | P42858 | 10/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 7/20 | 0.68 |
| ▸ | ATM | Q13315 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | MITF | O75030 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | CDC25A | P30304 | 3/20 | 0.63 |
| ▸ | CDC25B | P30305 | 3/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.63 |
| ▸ | NSD2 | O96028 | 2/20 | 0.63 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7240445 | 0.82 | MAPT (0.74) | MAPTRAB9AHTTKMT2ANPSR1 | |
| SCHEMBL29633261 | 0.81 | MAPT (1.00) | MAPTRAB9AHTTKMT2ANPSR1 | |
| SCHEMBL6506683 | 0.81 | MAPT (1.00) | MAPTRAB9AHTTKMT2ANPSR1 | |
| SCHEMBL24327533 | 0.78 | MAPT (0.44) | MAPTRAB9AHTTKMT2ANPSR1 | |
| SCHEMBL1243522 | 0.78 | MAPT (0.73) | MAPTRAB9AHTTKMT2ANPSR1 | |
| SCHEMBL11786902 | 0.76 | GNG2 (0.67) | MAPTKMT2AMEN1MAPK1LMNA | |
| SCHEMBL32664539 | 0.75 | MAPT (0.79) | MAPTRAB9AHTTKMT2ANPSR1 | |
| SCHEMBL31682570 | 0.75 | RAB9A (0.62) | MAPTRAB9AHTTKMT2ANPSR1 | |
| SCHEMBL7118329 | 0.75 | MAPT (0.59) | MAPTRAB9AHTTKMT2ANPSR1 | |
| SCHEMBL1242311 | 0.74 | MAPT (0.67) | MAPTRAB9AHTTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2021-08-10 | — | — | US | disclosed |
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2021-08-10 | — | — | US | disclosed |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-12-10 | — | — | US | disclosed |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-12-10 | — | — | US | disclosed |
| US-10745350-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-08-18 | — | — | US | disclosed |
| US-10745350-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-08-18 | — | — | US | disclosed |
| EP-3328368-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | BRIDGENT BIOTECHNOLOGY INC (TW) | 2020-07-15 | — | — | EP | disclosed |
| EP-3328368-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | BRIDGENT BIOTECHNOLOGY INC (TW) | 2020-07-15 | — | — | EP | disclosed |
| US-20190144383-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2019-05-16 | — | — | US | disclosed |
| US-20190144383-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2019-05-16 | — | — | US | disclosed |
| EP-3328368-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | Taipei Medical University (TW) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017020030-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017020030-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-02-02 | — | — | WO | disclosed |
| WO-2006011136-A9 | NOVEL NAPHTHOQUINONE DERIVATIVES AND USES THEREOF | VELOPMENT AUTHORITY BEN GURION (IL) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144383-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | PSMC1, PSME3, PSMB1 | MAPT 308/4885RAB9A 1884/4885HTT 209/4885 |
| US-10745350-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | PSMC1, PSME3, PSMB1 | MAPT 308/4885RAB9A 1884/4885HTT 209/4885 |
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | PSMC1, PSME3, PSMB1 | MAPT 308/4885RAB9A 1884/4885HTT 209/4885 |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | PSMC1, PSME3, PSMB1 | MAPT 308/4885RAB9A 1884/4885HTT 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.